Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease.
CONCLUSION: Although the efficacy of nivolumab in real-world patients was comparable to that seen in clinical trials, clinicians should be aware of HPD because it is not uncommon and represents a worse prognosis.
PMID: 32583235 [PubMed - indexed for MEDLINE]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Kim SH, Choi CM, Lee DH, Kim SW, Yoon S, Kim WS, Ji W, Lee JC Tags: J Cancer Res Clin Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Lung Cancer | Non-Small Cell Lung Cancer | Study